Combined radiochemotherapy in patients with locally advanced pancreatic cancer: A meta-analysis

Table 1 Characteristics of the eligible trials included in the meta-analysis

Ref.	Treatment arms	No. of participants	Sex (male/female)	Median age (yr)	PS 0-2/KPS≥50	Pathology (W/M/P/other)	Location of primary tumor(head of pancreas/other)	Jad score
Loehrer et al[9]	RT 50.4 Gy + GEM vs GEM	37	18/19	67	100%	4/6/5/22	12/25
		34	19/15	65.3	100%	6/8/7/13	20/14	3
Klaassen et al[10]	RT 40 Gy + 5FU vs 5FU	44	31/13		100%	NR	NR
		47	22/25	NR	100%			3
Moertel et al[11]	RT 35-40 Gy + saline vs RT 35-40 Gy + 5FU	32	NR	NR	NR	NR	NR
		32						4
GITSG et al[12]	RT 60 Gy vs RT 60Gy + 5FU vs RT 40 Gy + 5FU	28	12/16	NR	100%	8/17/3/0	10/18
		32	17/15		100%	6/20/6/0	9/23	3
		29	16/13		100%	6/18/5/0	6/23
Cohen et al[13]	RT 59.4 Gy vs RT 59.4 Gy + 5FU + MMC	49	27/22	62	100%	7/21/11/10	NR
		55	37/18	64	100%	12/19/17/7		3
Chauffert et al[6]	RT 60 Gy + 5FU + DDP + GEM vs GEM	59	31/28	60	100%	NR	46/13
		60	34/26	62	100%		40/20	3
Moertel et al[14]	RT 60 Gy vs RT 60 Gy + 5FU vs RT 40 Gy + 5FU	25		54	88%	5/8/2/10	8/17	3
		86		60	95%	20/39/9/14	68/18
		83		61	95%	13/30/9/31	64/19
Sun et al[15]	RT 45-50 Gy + GEM vs GEM	25	32/22	NR	100%	NR	NR	3
		29			100%
Sun et al[16]	RT 50-60 Gy + GEM vs GEM + DDP	26	33/23	NR	100%	NR	NR	3
		30			100%
Wu et al[17]	RT 48-56 Gy vs RT 48-60 Gy + GEM + DDP	31	50/14	57	98%	NR	NR	3
		33		57	99%
Wu et al[18]	RT 60 Gy vs RT 50 Gy + GEM	34	43/27	NR	87%	NR	NR	3
		36			90%
Ding et al[19]	RT 45-50 Gy + 5FU + GEM vs 5FU + GEM	25	32/22	NR	100%	NR	NR	3
		29			100%
Childs et al[20]	RT 35-40 Gy + saline vs RT 35-40 Gy + 5FU	12	11/1	58.8	NR	NR	NR	4
		13	8/5	56.3
GITSG et al[21]	RT 54 Gy + 5FU + SMF vs SMF	22	8/14	61	100%	NR	3/18	3
		21	8/13	60	100%		3/19
Hazel et al[22]	RT 46 Gy + 5FU vs 5FU + CCNU	15	10/5	62	NR	NR	NR	2
		15	10/5	62

W: Well differentiated; M: Moderately differentiated; P: Poorly differentiated; SMF: Streptozocin, mitomycin, and 5-fluorouracil (5FU); NR: No report; GEM: Gemcitabine; RT: radiotherapy alone; MMC: Mitomycin C.

Table 2 Overall survival and treatment-related toxicity of the eligible trials included in the meta-analysis

Ref.	Treatment arms	Participants	Overall survival (n)			3-4 grade treatment-related toxicity (n)
			6 mo	12 mo	18 mo	Hematological	Non-hematological
Loehrer et al[9]	RT 50.4 Gy + GEM vs GEM	37	28	12	4	29
		34	26	17	10	26
Klaassen et al[10]	RT 40 Gy + 5FU vs 5FU	44	25	14	11	8	NR
		47	28	12	5	1
Moertel et al[11]	RT 35-40 Gy + saline vs RT 35-40 Gy + 5FU	32	15	3	0	12	13
		32	20	6	1	24	24
GITSG et al[12]	RT 60 Gy vs RT 60 Gy + 5FU vs RT 40 Gy + 5FU	28	10	2	0
		32	25	11	3	NR	NR
		29	19	11	4
Cohen et al[13]	RT 59.4 Gy vs RT 59.4 Gy + 5FU + MMC	49	28	10	2	5	13
		55	36	17	5	13	17
Chauffert et al[6]	RT 60 Gy + 5FU + DDP + GEM vs GEM	59	47	20	11	29	12
		60	49	33	21	12	11
Moertel et al[14]	RT 60 Gy vs RT 60 Gy + 5FU vs RT 40 Gy + 5FU	25	13	6	4	4	0
		86	74	52	34	53	22
		83	63	49	40	39	18
Sun et al[15]	RT 45-50 Gy + GEM vs GEM	25	18	12	NR	5	5
		29	15	7		5	4
Sun et al[16]	RT 50-60 Gy + GEM vs GEM + DDP	26	21	16	NR	3	6
		30	18	11		3	10
Wu et al[17]	RT 48-56 Gy vs RT 48-60 Gy + GEM + DDP	31	NR	9	NR	NR	NR
		33		7
Wu et al[18]	RT 60 Gy vs RT 50 Gy + GEM	34	NR	5	NR	0	NR
		36		11		2
Ding et al[19]	RT 45-50 Gy + 5FU + GEM vs 5FU + GEM	25	18	12	NR	5	5
		29	15	7		5	4
Childs et al[20]	RT 35-40 Gy + saline vs RT 35-40 Gy + 5FU	12	4	1	NR	2	5
		13	6	2		8	9
GITSG et al[21]	RT 54 Gy + 5FU + SMF vs SMF	22	19	9	4	14	3
		21	17	4	0	3	3
Hazel et al[22]	RT 46 Gy + 5FU vs 5FU + CCNU	15	NR	NR	2	NR	NR
		15			1

RT: Radiotherapy alone; NR: No report.